ABSTRACT
An environmentally friendly, versatile multicomponent reaction for synthesizing isoxazol-5-one and pyrazol-3-one derivatives has been developed, utilizing a freshly prepared g-C3N4·OH nanocomposite as a highly efficient catalyst at room temperature in aqueous environment. This innovative approach yielded all the desired products with exceptionally high yields and concise reaction durations. The catalyst was well characterized by FT-IR, XRD, SEM, EDAX, and TGA/DTA studies. Notably, the catalyst demonstrated outstanding recyclability, maintaining its catalytic efficacy over six consecutive cycles without any loss. The sustainability of this methodology was assessed through various eco-friendly parameters, including E-factor and eco-score, confirming its viability as a green synthetic route in organic chemistry. Additionally, the gram-scale synthesis verifies its potential for industrial applications. The ten synthesized compounds were also analyzed via a PASS online tool to check their several pharmacological activities. The study is complemented by in silico molecular docking, pharmacokinetics, and molecular dynamics simulation studies. These studies discover 5D as a potential candidate for drug development, supported by its favorable drug-like properties, ADMET studies, docking interaction, and stable behavior in the protein binding cavity.
Subject(s)
Isoxazoles , Molecular Docking Simulation , Nanocomposites , Pyrazolones , Nanocomposites/chemistry , Pyrazolones/chemistry , Pyrazolones/chemical synthesis , Pyrazolones/pharmacokinetics , Isoxazoles/chemistry , Isoxazoles/pharmacokinetics , Graphite/chemistry , Catalysis , Molecular Dynamics Simulation , Nitriles/chemistry , Nitrogen Compounds/chemistry , Nitrogen Compounds/chemical synthesisABSTRACT
AIMS: The pharmacokinetics (PK) of hetrombopag were found to be nonlinear across evaluated dose ranges. The aim of this study was to develop a mechanism-based population pharmacokinetic/pharmacodynamic (PopPK/PD) model and to provide a reasonable expected therapeutic dose for a future confirmatory clinical study of hetrombopag. METHODS: Nonlinear mixed-effects modelling was performed using pooled 2168 hetrombopag concentrations and 1526 platelet counts from 72 healthy subjects and 32 chronic idiopathic thrombocytopenic purpura (ITP) patients from two phase I studies and one phase II study. The final model was evaluated via goodness-of-fit plots, visual predictive check and nonparametric bootstrap. Simulations from the validated PopPK/PD model were used to devise an expected therapeutic dose for later confirmatory clinical study. RESULTS: The pharmacokinetic data of hetrombopag were well described by a modified target-mediated drug disposition (TMDD) model with dual sequential first-order absorption. Mean parameter estimates (interindividual variability) were CL/F 7.66 L/h (63.5%), Vc /F 30.0 L (77.2%) and Kdeg 0.693/h (87.1%). The pharmacodynamic profile was well described by a five-compartment lifespan model with four-transit and one-platelet compartments. Simulation results suggested that chronic ITP patients following 10 mg once-daily hetrombopag would able to achieve an ideal platelet count level (50-200 × 109 /L). CONCLUSION: TMDD was the primary reason leading to nonlinear PK profile of hetrombopag. Our PK/PD modelling and simulation results support 10 mg once-daily as the recommended therapeutic dose for chronic ITP patients in subsequent confirmatory clinical study of hetrombopag.
Subject(s)
Purpura, Thrombocytopenic, Idiopathic , Pyrazolones , China , Clinical Trials, Phase I as Topic , Clinical Trials, Phase II as Topic , Healthy Volunteers , Humans , Hydrazones , Models, Biological , Purpura, Thrombocytopenic, Idiopathic/drug therapy , Pyrazolones/pharmacokineticsABSTRACT
A population pharmacokinetic (PK) analysis was conducted to characterize sources of interpatient variability on the PK of TAK-931, a cell division cycle 7 kinase inhibitor, in adult patients with advanced solid tumors using data from 198 patients who received oral TAK-931 over the range of 30 to 150 mg once daily in multiple dosing schedules in 2 phase 1 and 1 phase 2 clinical studies. A 2-compartment model with 2 transit compartments describing the absorption and first-order linear elimination adequately described the PK of TAK-931. The apparent oral clearance (CL/F) of TAK-931 was estimated to be 38 L/h, and the terminal half-life was estimated to be approximately 6 hours. Creatinine clearance (CrCL) was identified as a covariate on CL/F, and body weight as a covariate on CL/F, apparent central volume of distribution, and apparent intercompartmental clearance. Simulations using the final model indicated that the effect of CrCL (≥35 mL/min) or body weight (29.8-127 kg) on TAK-931 systemic exposures was not considered clinically meaningful, suggesting that no dose adjustments were necessary to account for body weight or renal function (CrCL ≥35 mL/min). Sex, age (36-88 years), race, and mild hepatic impairment had no impact on the CL/F of TAK-931. Taken together, the population PK analysis supports the same starting dose of TAK-931 in Asian and Western cancer patients in a global setting.
Subject(s)
Antineoplastic Agents/pharmacokinetics , Cell Cycle Proteins/antagonists & inhibitors , Neoplasms/drug therapy , Protein Serine-Threonine Kinases/antagonists & inhibitors , Pyrazolones/pharmacokinetics , Pyrimidines/pharmacokinetics , Adult , Aged , Area Under Curve , Biological Transport , Computer Simulation , Creatinine/blood , Dose-Response Relationship, Drug , Female , Humans , Liver Failure/metabolism , Male , Metabolic Clearance Rate , Middle Aged , Racial GroupsABSTRACT
Hetrombopag (Hengqu®), an oral nonpeptide thrombopoietin receptor agonist, is being developed by Jiangsu Hengrui Pharmaceutical for the treatment of thrombocytopenia and aplastic anaemia. On 16 June 2021, hetrombopag received its first approval in China as a second-line treatment for primary immune thrombocytopenia (ITP) and severe aplastic anaemia (SAA) in adults. The drug is also undergoing phase III development in China for the treatment of chemotherapy-induced thrombocytopenia. This article summarizes the milestones in the development of hetrombopag leading to this first approval for ITP and SAA.
Subject(s)
Anemia, Aplastic/drug therapy , Hydrazones/pharmacology , Hydrazones/therapeutic use , Pyrazolones/pharmacology , Pyrazolones/therapeutic use , Thrombocytopenia/drug therapy , China , Clinical Trials as Topic , Drug Approval , Humans , Hydrazones/pharmacokinetics , Pyrazolones/pharmacokinetics , United StatesABSTRACT
PURPOSE: Hetrombopag, a novel, oral small molecule thrombopoietin receptor agonist, exhibits an obvious thrombocytopoietic effect with good safety. Hetrombopag is currently under clinical development for the treatment of chronic idiopathic thrombocytopenic purpura (ITP). The objectives of this study were to assess the effect of high-fat and high-calorie food on the pharmacokinetic and pharmacodynamic (PK/PD) profiles of hetrombopag in healthy volunteers. METHODS: An independent, single-dose, open-label, randomized-sequence, crossover trial was conducted. Healthy volunteers received hetrombopag 7.5-mg tablets in the fasted state or with a high-fat, high-calorie breakfast. The effects of the high-fat and high-calorie food on the PK/PD profiles of hetrombopag were evaluated by using a noncompartmental analysis and a semi-physiological model. FINDINGS: Twelve Chinese healthy volunteers were enrolled. Mean plasma AUC0-t and Cmax decreased by 98.7% and 95.0%, respectively, when hetrombopag was administered with high-fat and high-calorie food. The semi-physiological PK/PD model analysis showed that the absorption rate constant at the first absorption site was almost halved at the fed condition. The change in platelet counts in the fed condition was not sufficiently as sensitive as that in the fasted condition. IMPLICATIONS: High-fat and high-calorie food were associated with significantly reduced systemic exposure and platelet count sensitivity. Thus, hetrombopag should be taken in a fasted state to avoid the impact of food on bioavailability and platelet counts. ClinicalTrials.gov identifier: NCT02409394.
Subject(s)
Food-Drug Interactions , Hydrazones/pharmacology , Hydrazones/pharmacokinetics , Pyrazolones/pharmacology , Pyrazolones/pharmacokinetics , Administration, Oral , Adult , Area Under Curve , Biological Availability , Cross-Over Studies , Dietary Fats/administration & dosage , Fasting/metabolism , Female , Healthy Volunteers , Humans , Hydrazones/blood , Male , Platelet Count , Pyrazolones/blood , Tablets , Young AdultABSTRACT
AIMS: Hetrombopag olamine is a novel small-molecule, nonpeptide thrombopoietin receptor agonist developed for immune thrombocytopenia treatment. This study aims to determine the safety and the effect of fasting duration after administration of hetrombopag on pharmacokinetics and pharmacodynamics in Chinese healthy subjects. METHODS: A randomized, open-label, single-dose, 3-period crossover, self-control trial was conducted. 15 eligible subjects were enrolled and received hetrombopag 7.5 mg at day 1 of each period followed by a standard meal 4 hours postdose (treatment A/fasting condition), or a high-calorie, high-fat meal 1 hour postdose (treatment B), or a high-calorie, high-fat meal 2 hours postdose (treatment C). The plasma concentrations of hetrombopag were determined by validated liquid chromatography-tandem mass spectrometry, platelet counts were quantified by blood test. Analysis was performed using a mixed model, including treatment, period as fixed effects and participant as a random effect. RESULTS: Compared with treatment A, peak concentration and area under concentration-time curve extrapolated to infinity decreased by 56 and 74.6%, and 44 and 61% in treatments B and C, respectively. The mean platelet number on day 6 increased by 15.8, 6.96 and 10.26%, respectively, in treatments A, B and C in comparison with baseline platelet level. No severe adverse events happened in any of the 3 treatments. CONCLUSION: Hetrombopag was well tolerated in healthy male subjects under fasted/fed conditions. The shorter fasting duration resulted in lower hetrombopag exposure, corresponding to a lower level of platelet elevation. Therefore, we recommended oral administration of hetrombopag on an empty stomach (fasting condition) or at least 2 hours before a meal to achieve maximum bioavailability.
Subject(s)
Fasting , Food-Drug Interactions , Hydrazones/administration & dosage , Pyrazolones/administration & dosage , Administration, Oral , Area Under Curve , Biological Availability , Cross-Over Studies , Female , Half-Life , Healthy Volunteers , Humans , Hydrazones/pharmacokinetics , Male , Pyrazolones/pharmacokineticsABSTRACT
Hetrombopag olamine (hetrombopag) is a novel small-molecule, orally bioavailable, non-peptide thrombopoietin (TPO) receptor agonist that is being developed as the treatment for thrombocytopenia. Two randomized, placebo-controlled phase I studies were conducted in 72 healthy individuals to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of hetrombopag. Hetrombopag was orally administered with a single dose in five dose cohorts (5 mg, 10 mg, 20 mg, 30 mg or 40 mg) in the first study, and given once daily for 10 days in three dose cohorts (2.5 mg, 5.0 mg or 7.5 mg) in the second study, respectively. Hetrombopag was well tolerated, and the majority of adverse events associated with medicine were platelet elevations significantly above the normal range in healthy individuals. The single dose-escalation study revealed a Tmax of approximate 8 hr, and a t1/2 of 11.9 hr to 40.1 hr in a dose-prolonged manner. A dose-proportional increase in maximum concentration (Cmax ) of hetrombopag was observed, with area under the curve (AUC) increasing in a greater than dose-proportional manner. The plasma concentration of hetrombopag reached the steady-state after 7 days. The steady-state AUC0-24 hr and Cmax were dose-proportionally elevated from the 5.0 mg to 7.5 mg dose level. The potent pharmacological effect of the hetrombopag-induced platelet elevation was observed in a time- and dose-dependent manner. Furthermore, the thrombopoietic response was significantly (p < 0.0001) correlated to the plasma exposure level of hetrombopag in single and multiple administration studies. Taken together, results of this study support further clinical development of hetrombopag in patients with thrombocytopenia.
Subject(s)
Hydrazones/administration & dosage , Pyrazolones/administration & dosage , Receptors, Thrombopoietin/agonists , Administration, Oral , Area Under Curve , Blood Platelets/metabolism , Dose-Response Relationship, Drug , Double-Blind Method , Half-Life , Humans , Hydrazones/pharmacokinetics , Hydrazones/pharmacology , Male , Pyrazolones/pharmacokinetics , Pyrazolones/pharmacology , Time FactorsABSTRACT
The arylsulfanylpyrazolone and aryloxanylpyrazolone scaffolds previously were reported to inhibit Cu/Zn superoxide dismutase 1 dependent protein aggregation and to extend survival in the ALS mouse model. However, further evaluation of these compounds indicated weak pharmacokinetic properties and a relatively low maximum tolerated dose. On the basis of an ADME analysis, a new series of compounds, the arylazanylpyrazolones, has been synthesized, and structure-activity relationships were determined. The SAR results showed that the pyrazolone ring is critical to cellular protection. The NMR, IR, and computational analyses suggest that phenol-type tautomers of the pyrazolone ring are the active pharmacophore with the arylazanylpyrazolone analogues. A comparison of experimental and calculated IR spectra is shown to be a valuable method to identify the predominant tautomer.
Subject(s)
Amyotrophic Lateral Sclerosis/drug therapy , Mutation , Protein Multimerization/drug effects , Pyrazolones/chemistry , Pyrazolones/pharmacology , Superoxide Dismutase/metabolism , Animals , Caco-2 Cells , Humans , Mice , Protein Structure, Quaternary , Pyrazolones/pharmacokinetics , Pyrazolones/therapeutic use , Structure-Activity Relationship , Superoxide Dismutase/genetics , Superoxide Dismutase-1ABSTRACT
Deregulation of c-Met receptor tyrosine kinase activity leads to tumorigenesis and metastasis in animal models. More importantly, the identification of activating mutations in c-Met, as well as MET gene amplification in human cancers, points to c-Met as an important target for cancer therapy. We have previously described two classes of c-Met kinase inhibitors (class I and class II) that differ in their binding modes and selectivity profiles. The class II inhibitors tend to have activities on multiple kinases. Knowledge of the binding mode of these molecules in the c-Met protein led to the design and evaluation of several new class II c-Met inhibitors that utilize various 5-membered cyclic carboxamides to conformationally restrain key pharmacophoric groups within the molecule. These investigations resulted in the identification of a potent and novel class of pyrazolone c-Met inhibitors with good in vivo activity.
Subject(s)
Antineoplastic Agents/chemical synthesis , Proto-Oncogene Proteins c-met/antagonists & inhibitors , Pyrazolones/chemical synthesis , Animals , Antineoplastic Agents/pharmacokinetics , Antineoplastic Agents/pharmacology , Cell Line, Tumor , Crystallography, X-Ray , Drug Design , Humans , Liver/metabolism , Male , Mice , Mice, Inbred BALB C , Models, Molecular , Phosphorylation , Protein Conformation , Proto-Oncogene Proteins c-met/metabolism , Pyrazolones/pharmacokinetics , Pyrazolones/pharmacology , Rats , Rats, Sprague-Dawley , Receptor, IGF Type 1/antagonists & inhibitors , Structure-Activity Relationship , Vascular Endothelial Growth Factor Receptor-2/antagonists & inhibitorsABSTRACT
A series of pyrazoloquinolines, possessing (hetero)arylhydroxymethyl substituents at the quinoline C-4 position were evaluated as PDE10A inhibitors. Among these, methylpyrimidyl analogue 15 was identified as having good rodent and monkey exposure, and a MED of 10 mg/kg in an in vivo model.
Subject(s)
Drug Discovery , Enzyme Inhibitors/pharmacology , Phosphoric Diester Hydrolases/metabolism , Quinolines/chemistry , Quinolines/pharmacology , Animals , Enzyme Activation/drug effects , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/pharmacokinetics , Haplorhini , Hepatocytes/drug effects , Hepatocytes/metabolism , Inhibitory Concentration 50 , Molecular Structure , Pyrazolones/chemical synthesis , Pyrazolones/chemistry , Pyrazolones/pharmacokinetics , Pyrazolones/pharmacology , Quinolines/chemical synthesis , Quinolines/pharmacokinetics , RatsABSTRACT
Amyotrophic lateral sclerosis (ALS) is an orphan neurodegenerative disease currently without a cure. The arylsulfanyl pyrazolone (ASP) scaffold was one of the active scaffolds identified in a cell-based high throughput screening assay targeting mutant Cu/Zn superoxide dismutase 1 (SOD1) induced toxicity and aggregation as a marker for ALS. The initial ASP hit compounds were potent and had favorable ADME properties but had poor microsomal and plasma stability. Here, we identify the microsomal metabolite and describe synthesized analogues of these ASP compounds to address the rapid metabolism. Both in vitro potency and pharmacological properties of the ASP scaffold have been dramatically improved via chemical modification to the corresponding sulfone and ether derivatives. One of the ether analogues (13), with superior potency and in vitro pharmacokinetic properties, was tested in vivo for its pharmacokinetic profile, brain penetration, and efficacy in an ALS mouse model. The analogue showed sustained blood and brain levels in vivo and significant activity in the mouse model of ALS, thus validating the new aryloxanyl pyrazolone scaffold as an important novel therapeutic lead for the treatment of this neurodegenerative disorder.
Subject(s)
Amyotrophic Lateral Sclerosis/drug therapy , Pyrazoles/chemical synthesis , Pyrazolones/chemical synthesis , Superoxide Dismutase/antagonists & inhibitors , Animals , Blood-Brain Barrier/metabolism , Caco-2 Cells , Cell Membrane Permeability , Cytochrome P-450 Enzyme Inhibitors , Drug Design , ERG1 Potassium Channel , Ether-A-Go-Go Potassium Channels/antagonists & inhibitors , Ethers/chemical synthesis , Ethers/pharmacokinetics , Ethers/pharmacology , HEK293 Cells , Humans , In Vitro Techniques , Mice , Microsomes, Liver/metabolism , Mutation , Neurons/cytology , Neurons/drug effects , Pyrazoles/pharmacokinetics , Pyrazoles/pharmacology , Pyrazolones/pharmacokinetics , Pyrazolones/pharmacology , Rats , Rats, Sprague-Dawley , Solubility , Structure-Activity Relationship , Sulfones/chemical synthesis , Sulfones/pharmacokinetics , Sulfones/pharmacology , Superoxide Dismutase/genetics , Superoxide Dismutase-1ABSTRACT
Anaplastic lymphoma kinase (ALK) is transmembrane receptor tyrosine kinase, with oncogenic variants that have been implicated in ALCL, NSCLC and other cancers. Screening of a VEGFR2-biased kinase library resulted in identification of 1 which showed cross-reactivity with ALK. SAR on the indole segment of 1 showed that a subtle structural modification (the ethoxy group of 1 changed to a benzyloxy to generate 5a) enhanced potency (ALK), selectivity for VEGFR2 and IR along with improvement in metabolic stability. From docking studies of ALK versus VEGFR2 kinase, we postulated that the loss of entropy of the VEGFR2 in the bound form with 5a might be the origin of the reduced activity against that protein. Modification of the heterocyclic segment showed that thiazole-bearing pyrazolones preserved enzyme potency, and enhanced inhibition of NPM-ALK autophosphorylation in ALK-positive ALCL cells (Karpas-299). SAR of the benzyloxy group resulted in compounds which demonstrated good cellular potency in Karpas-299 cells. Compound 8 showed best overall profile for the series with broad kinome selectivity and liver micorsome stability. Compound 8 showed reasonable iv PK in rat, but with little oral exposure.
Subject(s)
Protein Kinase Inhibitors/chemistry , Pyrazolones/chemistry , Receptor Protein-Tyrosine Kinases/antagonists & inhibitors , Administration, Oral , Anaplastic Lymphoma Kinase , Animals , Binding Sites , Cell Line, Tumor , Computer Simulation , Enzyme Activation/drug effects , Indoles/chemistry , Protein Kinase Inhibitors/chemical synthesis , Protein Kinase Inhibitors/pharmacokinetics , Protein Kinase Inhibitors/pharmacology , Protein Structure, Tertiary , Pyrazolones/chemical synthesis , Pyrazolones/pharmacokinetics , Pyrazolones/pharmacology , Rats , Receptor Protein-Tyrosine Kinases/metabolism , Structure-Activity Relationship , Vascular Endothelial Growth Factor Receptor-2/antagonists & inhibitors , Vascular Endothelial Growth Factor Receptor-2/metabolismABSTRACT
3-Methyl-1-phenyl-2-pyrazolin-5-one (edaravone, 1), known as a potent free radical scavenger, has been developed as a medical drug for the treatment of acute cerebral infarction. With the aim of developing radiotracers for imaging free radicals in vivo, 1-(3'-[(125)I]iodophenyl)-3-methy-2-pyrazolin-5-one ((125)I-2) was synthesized by two methods, via isotopic exchange and interhalogen exchange under solvent-free conditions, in which iodo- and bromo-derivatives were used as labeling precursors, respectively. After HPLC purification, (125)I-2 was obtained in modest isolated radiochemical yields (ca. 20%) with high radiochemical purities by both methods. The former gave specific activities of 0.2-0.6 kBq/micromol, whereas the latter approach achieved specific activities of more than 0.14 GBq/micromol. On attempting to prepare an injectable formulation for (125)I-2 with high specific activity, its radiochemical purities dropped to about 60-70%. Unlabeled analog 2 was found to have lipophilic and antioxidant properties similar to edaravone. Intravenous injection of (125)I-2 with low specific radioactivity into normal mice showed signs of distribution profiles similar to reported results for (14)C-labeled edaravone in normal rats.
Subject(s)
Antioxidants/chemical synthesis , Antioxidants/pharmacokinetics , Antipyrine/analogs & derivatives , Pyrazolones/chemistry , Pyrazolones/pharmacokinetics , Animals , Antioxidants/administration & dosage , Antioxidants/chemistry , Antipyrine/administration & dosage , Antipyrine/chemical synthesis , Antipyrine/chemistry , Antipyrine/pharmacokinetics , Drug Stability , Edaravone , Male , Mice , Mice, Inbred ICR , Molecular Structure , Pyrazolones/administration & dosage , Pyrazolones/chemical synthesis , Solubility , Tissue DistributionABSTRACT
Interruption of TGFbeta signaling through inhibition of the TGFbetaR1 kinase domain may prove to have beneficial effect in both fibrotic and oncological diseases. Herein we describe the SAR of a novel series of TGFbetaR1 kinase inhibitors containing a pyrazolone core. Most TGFbetaR1 kinase inhibitors described to date contain a core five-membered ring bearing N as H-bond acceptor. Described herein is a novel strategy to replace the core structure with pyrazolone ring, in which the carbonyl group is designed as an H-bond acceptor to interact with catalytic Lys 232.
Subject(s)
Protein Kinase Inhibitors/chemistry , Protein Serine-Threonine Kinases/antagonists & inhibitors , Pyrazolones/chemistry , Receptors, Transforming Growth Factor beta/antagonists & inhibitors , Animals , Binding Sites , Crystallography, X-Ray , Mice , Protein Kinase Inhibitors/chemical synthesis , Protein Kinase Inhibitors/pharmacokinetics , Protein Serine-Threonine Kinases/metabolism , Pyrazolones/chemical synthesis , Pyrazolones/pharmacokinetics , Rats , Receptor, Transforming Growth Factor-beta Type I , Receptors, Transforming Growth Factor beta/metabolism , Structure-Activity RelationshipABSTRACT
KDR kinase inhibition is considered to play an important role in regulating angiogenesis, which is vital for the survival and proliferation of tumor cells. Recently we disclosed a structure-based kinase inhibitor design strategy which led to the identification of a new class of VEGFR-2/KDR kinase inhibitors bearing heterocyclic substituted pyrazolones as the core template. Instability in a rat S9 preparation and poor iv PK profiles for most of these inhibitors necessitated exploration of new pyrazolones to identify new analogs with improved metabolic stability. Optimization of the heterocyclic moiety led to the identification of the thiadiazole series of pyrazolones (D) as potent VEGFR-2/KDR kinase inhibitors. SAR modifications, kinase selectivity profiling, and structural elements for improved PK properties were explored. Oral bioavailability up to 29% was achieved in the rat. Modeling results based on the Glide XP docking approach supported our postulation regarding the interaction of the lactam segment of the pyrazolones with the hinge region of the KDR kinase.
Subject(s)
Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/pharmacology , Pyrazolones/chemical synthesis , Pyrazolones/pharmacology , Vascular Endothelial Growth Factor Receptor-2/antagonists & inhibitors , Animals , Autoradiography , Biological Availability , Blotting, Western , Drug Design , Enzyme Inhibitors/pharmacokinetics , Humans , In Vitro Techniques , Models, Molecular , Protease Inhibitors/chemical synthesis , Protease Inhibitors/pharmacology , Pyrazolones/pharmacokinetics , Rats , Recombinant Proteins , Spectrometry, Fluorescence , Structure-Activity RelationshipABSTRACT
We have described the synthesis of tridentate pyrazolyl ligand frameworks for coordination to the fac-[*M(CO)(3)](+) metal fragment (*M=(186/188)Re or (99m)Tc). These ligands impart a degree of kinetic inertness on the metal center, warranting their study in biological systems. We herein report in vitro/in vivo radiolabeling investigations of a new series of pyrazolyl bombesin (BBN) conjugates radiolabeled via the Isolink kit. These new conjugates are based on the general structure [(99m)Tc-pyrazolyl-X-BBN[7-14]NH(2)], where X=beta-alanine, serylserylserine or glycylglycylglycine. The pyrazolyl ligand is a tridentate ligand framework that coordinates the metal center through nitrogen donor atoms. The results of these investigations demonstrate the ability of these new conjugates to specifically target the gastrin-releasing peptide receptor subtype 2, which is overexpressed on human prostate PC-3 cancerous tissues. Therefore, these studies suggest the tridentate pyrazolyl ligand framework to be an ideal candidate for the design and development of low-valent (99m)Tc-based diagnostic radiopharmaceuticals based on BBN or other targeting vectors.
Subject(s)
Bombesin/pharmacokinetics , Prostatic Neoplasms/diagnostic imaging , Prostatic Neoplasms/metabolism , Animals , Drug Stability , Humans , Isotope Labeling/methods , Ligands , Male , Metabolic Clearance Rate , Mice , Mice, SCID , Organ Specificity , Pyrazolones/pharmacokinetics , Radioligand Assay/methods , Radionuclide Imaging , Radiopharmaceuticals/chemical synthesis , Radiopharmaceuticals/pharmacokinetics , Tissue DistributionABSTRACT
One of the 14 different drugs known to be metabolized to methamphetamine and/or amphetamine is famprofazone, a component in the multi-ingredient formulation Gewodin. Because of its conversion to methamphetamine and amphetamine, which can result in positive drug-testing results, the excretion pattern of these metabolites is critical for proper interpretation of drug-testing results. Multiple doses of famprofazone were administered to healthy volunteers with no previous history of methamphetamine, amphetamine, or famprofazone use. Following administration, urine samples were collected ad lib for nine days, and pH, specific gravity, and creatinine values were determined. To determine the methamphetamine and amphetamine excretion profile, samples were extracted, derivatized, and analyzed by gas chromatography-mass spectrometry (GC-MS). Peak concentrations of methamphetamine ranged from 5327 to 14,155 ng/mL and from 833 to 3555 ng/mL for amphetamine and were reached between 12:22 and 48:45 h post initial dose. There were 15-19 samples per subject that were positive under HHS testing guidelines, with the earliest at 03:37 h post initial dose and as late as 70:30 h post last dose. Methamphetamine and amphetamine were last detected (LOD > or = 5 ng/mL) up to 159 h and 153 h post last dose for methamphetamine and amphetamine, respectively. GC-MS was also used to determine the enantiomeric composition of methamphetamine and amphetamine. This analysis revealed both enantiomers were present in a predictable pattern.
Subject(s)
Methamphetamine/analogs & derivatives , Methamphetamine/pharmacokinetics , Pyrazolones/pharmacokinetics , Adult , Amphetamine/urine , Biotransformation , Creatinine/urine , Dealkylation , Female , Gas Chromatography-Mass Spectrometry , Humans , Hydrogen-Ion Concentration , Methamphetamine/administration & dosage , Methamphetamine/urine , Middle Aged , Pyrazolones/administration & dosage , Reference Standards , StereoisomerismABSTRACT
Novel substituted [5,5]-bicyclic pyrzazolones are presented as inhibitors of tumor necrosis factor-alpha (TNF-alpha) production. Many of these compounds show low nanomolar activity against lipopolysaccaride (LPS)-induced TNF-alpha production in THP-1 cells. This class of molecules was co-crystallized with mutated p38, and several analogs showed good oral bioavailability in the rat. Oral activity of these compounds in the rat iodoacetate model for osteoarthritis is discussed.